Trutino Biosciences Inc.

https://www.trutinobio.com

LinkedIn: https://www.linkedin.com/company/trutino-biosciences

Trutino Biosciences is a research-driven biopharmaceutical company with a mission to restore immuno-balance in cancer patients by developing the next generation cytokine therapies that can safely activate tumor-fighting immune cells at the disease site without causing adverse side effects. Trutino’s proprietary On-Demand-Cytokine™ (ODC) platform technology enables the design of therapeutic candidates that can be systemically delivered in an inactive cytokine form and be locally activated directly at the tumor site, thereby avoiding the extreme toxicity of conventional cytokine therapies, and potentially improving efficacy either as a single agent or in combination with other treatment modalities. Established in 2018, Trutino is developing an expansive menu of novel ZYTOKINES™ and ZYMOKINES™ derived from its ODC platform that trigger maximal cancer-fighting immune responses only at tumor sites without the risk of systemic toxicity. The company’s lead product candidate, ODC-IL2, has produced compelling preclinical data suggesting it is poised to become a best-in-class IL-2 therapy with the potential of enhanced synergies in combination therapy approaches. *

	Start	2018-01-01 established
	Industry	On-Demand-Cytokine™ platform technology (ODC platform technology)
	Industry 2	ODC-IL2 (Trutino Biosciences)
	Person	Kim, Phillip (Trutino Biosciences 202002 CEO + Founder)

	Region	San Diego, CA
	Country	United States (USA)
	Street	3210 Merryfield Row
	City	92121 San Diego, CA
	Tel	+1-858-880-5501
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: Boehringer Ingelheim. (2/27/20). "Press Release: Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform". Ingelheim & San Diego, CA.

		Record changed: 2023-07-10

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Trutino Biosciences Inc.

[1] Boehringer Ingelheim. (2/27/20). "Press Release: Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform". Ingelheim & San Diego, CA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]